drugset / Trial / NCT00219908
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
Phase 2
Terminated
124 enrolled
Rennes University Hospital
Bayer · collabFarmades, Italy · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupOpen-label
Summary
The aim of the study is to determine whether a therapeutic strategy combining mitoxantrone and interferon beta1b can delay disease progression of at least one point on EDSS scale in patients with clinically very active relapsing-remitting multiple sclerosis.
Timeline
- Start
- 1999-07
- Primary completion
- —
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitoxantrone | Small molecule | — | — |